We describe herein a patient presenting with bilateral ER+ breast tumors who was enrolled in a clinical trial exploring molecular aberrations associated with hormone-refractory tumor cell proliferation.
Introduction
A 60-year-old female presented to the Vanderbilt Breast Center with an abnormal mammogram showing scattered micro-calcifications and upper-quadrant nodularity in her left breast. A diagnostic mammogram and ultrasound (US) confirmed these findings. A core biopsy revealed the lesion to be an estrogen-receptor-positive (ER+), progesterone receptor-positive (PR+), HER2-negative, low grade invasive mammary carcinoma. The patient also had a palpable abnormality in the right breast, which upon US was identified as a hypoechoic lesion suspicious for malignancy. A core biopsy revealed it to be a low grade, ER+/HER2-negative invasive mammary carcinoma.
Prior to definitive breast surgery, the patient was consented and enrolled in a presurgical trial of with the aromatase inhibitor letrozole ( Figure 1A ; Vanderbilt University NCT00651976). This trial examines the short-term cellular and molecular response to estrogen deprivation with letrozole (2.5 mg QD for 10-21 days) in stage I and II operable ER+/HER2-negative breast cancer. Molecular correlates include gene expression, proteomic, and mutational screening to identify biomarkers and effectors of resistance to estrogen deprivation in cancers that do not exhibit a change in tumor cell proliferation and/or that retain a high proliferation as measured by Ki67 immunohistochemistry (IHC). The trial design is based in large part on the results of the IMPACT study, where tumor cell proliferation (measured by Ki67 IHC) after two weeks of antiestrogen therapy was a surrogate for long-term patient disease-free survival following adjuvant endocrine therapy(1-3).
The patient received 16 days of letrozole followed by bilateral mastectomy with sentinel lymph node biopsy the day after the last dose. Her final pathology was consistent with a right invasive mammary carcinoma, stage II (T1bN1; 0.9 cm, 2 involved lymph nodes), low histological grade, ER+, PR+, HER2-negative, and a left multicentric invasive mammary carcinoma, stage I (T1bN0; 0.7 cm, 0.5 cm), low histological grade, ER+, PR+, HER2-negative tumor. A follow-up right axillary dissection revealed that none of the 15 lymph nodes removed were involved by cancer. She subsequently underwent adjuvant chemotherapy (anthracycline/taxane) followed by 5 years of endocrine therapy. The patient continues to do well without evidence of recurrence since her original diagnosis on November 2008.
Materials and Methods
Formalin-fixed, paraffin-embedded (FFPE) pre-treatment core biopsies and post-treatment surgical specimens were utilized to assess the status of >400 known somatic oncogenic mutations in 33 genes as described (4) . Sanger sequencing was carried out to verify mutation status. Immunohistochemistry (IHC) was performed in both the pre-treatment biopsy and in the post-treatment surgical biopsy of both tumors for Ki67 (Dako #M7240), ERα (Santa Cruz #sc542), p-ERα S118 (Cell Signaling #2511), PR (Dako #M3569) and p-ERK1/2 (Cell Signaling, #9101). IHC for ER and PR was carried out according to the methods reported elsewhere (5). 
Results
An activating KRAS mutation (G12D) was identified in the left-breast tumor, while no screened mutations were identified in the tumor from the right breast. Of note, however, the total incidence of PIK3CA mutations identified in the initial analysis was ~40% (9/20 patients), which is similar to the reported frequency on the Catalogue of Somatic Mutations in Cancer (COSMIC) database (7) . The status of the G12 codon was confirmed by Sanger sequencing. Figure 1A demonstrates the c.35G>A transition resulting in the change from glycine to aspartic acid at Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. codon 12. The mutation was confirmed in the left tumor, but not the right tumor, in both the pretreatment core biopsy and surgical specimen in both the forward and reverse directions by PCR (primer sequence and conditions for KRAS exon 1 were previously described (8) ). The same tumor block utilized for IHC was used for DNA extraction and sequencing to eliminate the potential for left/right-sided errors.
The Ki67 score in the KRAS-G12D tumor decreased from 14 ± 2.5% (pre-treatment) to 1 ± 1% after letrozole, whereas Ki67 in the KRAS-WT tumor was essentially unchanged (4.5 ± 1.2% to 2.5 ± 1.2%; Figure 1B-C) . The KRAS-G12D tumor had a substantially higher Ki67 score at baseline than the KRAS-WT tumor (14% versus 4.5%, respectively). We calculated Allred scores(5) (noted in Figure 2A ) for ER and PR in the pre-and post-letrozole samples. ER scores were equivalent in both tumors, suggesting that the difference in proliferative response was not due to variations in ER expression. The PR score was higher in the KRAS-G12D tumor than in the KRAS-WT tumor (ALLRED scores of 6 and 3, respectively). Consistent with estrogen deprivation, PR expression decreased significantly in both tumors in response to letrozole.
ERα is phosphorylated at Serine-118 by ERK1/2, which lies downstream of KRAS, resulting in estrogen-independent transcriptional activity (9) . Therefore, we hypothesized that the KRAS-G12D tumor may have higher phosphorylation of ERK1/2 T202/Y204 and ERα
S118
. IHC for the phosphorylated epitopes of both proteins was performed. However, we did not observe any differences in P-ERα S118 signal between the tumors (data not shown). P-ERK1/2 T202/Y204 signal was high in both pre-treatment biopsies, but essentially absent in the post-treatment specimens, possibly reflecting sample-fixation issues known to induce rapid loss of phospho-ERK1/2 immunoreactivity(10). As ER S118 is also phosphorylated by estradiol-induced CDK7 (11) it is also plausible that letrozole-induced estrogen deprivation resulted in loss of ERK of loss of PI3K pathway activity, which is down regulated in breast tumors following letrozole treatment (12) . Although the tumor harboring KRAS-G12D exhibited a strong anti-proliferative response to estrogen deprivation, we questioned whether KRAS activation in this tumor may abrogate apoptotic pathways. Therefore, we also stained all 4 samples for the apoptotic marker cleaved caspase-3. Little or no cleaved caspase-3 staining was detected in any of the samples (data not shown), supporting a cytostatic but not an apoptotic effect of the aromatase inhibitor.
In examining gene expression data from the patient, we identified genes with the greatest differential expression between the KRAS-G12D and KRAS-WT tumor ( Figure 2B In contrast, the KRAS-WT tumor highly expressed the mRNA for the tyrosine kinase fibroblast growth factor receptor-1 (FGFR1). FISH analysis for FGFR1 confirmed genomic amplification of the 8p12 locus in the KRAS-WT, but not the KRAS-mutant tumor ( Figure 2C ), in both pre-and post-treatment specimens. Genomic amplification of FGFR1 has been directly linked with endocrine resistance (14) . We speculate that this finding may offer an explanation for the lack of change in Ki67 in this tumor. 
Activating mutations in KRAS are common in diverse cancer types, such as melanoma, colorectal, pancreatic, and non-small cell lung cancers. In lung and colorectal cancer, KRAS mutations have been associated with resistance to EGFR-targeted therapies, primarily due to decoupling of the Ras pathway from EGFR. Activating KRAS mutations are rare in breast cancer, and no data exist on whether KRAS mutations can induce resistance to anti-estrogen therapy. Correlative studies have identified an association between Ras pathway activation as defined by high levels of P-ERK1/2 Y202/T204 and P-RAF S338 and resistance to tamoxifen in patients with ER+ breast cancer (15) . However, mutational status of the pathway was not assessed in this study. Ras activation coupled with estrogenic stimuli can cooperatively enhance invasive phenotypes (16) . ER+ MCF-7 human breast cancer cells engineered to overexpress v-Ha-Ras were found to be less responsive to estrogen-induced proliferation and tamoxifen-induced inhibition of proliferation (17) . It is intuitive that by conferring a gain of function, KRAS mutations should confer estrogen-independent growth and survival in an ER+ tumor. However, based on the cellular markers assessed in this case, the evidence does not support the hypothesis that KRAS mutations confer resistance to estrogen deprivation in ER+ breast cancer. However, it is noteworthy that the KRAS-mutant tumor demonstrated higher Ki67 staining, and thus may be a poor prognostic marker per se as is observed in other cancers.
The contribution of FGFR1 amplification to endocrine resistance in breast cancer is clearer. Recent work showed that FGFR1 amplification occurs in approximately 10% of breast cancers (predominantly ER+ and HER2-negative), is a poor prognostic factor, and can directly compensate for loss of estrogen signaling through estrogen-dependent or -independent PI3K
and MAPK activation (14, 18, 19) . control, we provide evidence supporting a role for FGFR1 in resistance to endocrine therapy.
These findings support further exploration of the utility of FGFR1-targeted agents for the treatment of endocrine-resistant breast cancer. 
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